Wedbush Reiterates Buy Rating on KNSA
Wedbush maintains its buy rating on KNSA with a $72 price target, a 15.37% upside from the current price.
Key Points
- Wedbush analyst David Nierengarten reiterated a buy rating on KNSA with a price target of $72 on June 29, 2026.
- Wedbush's $72 price target implies 15.37% upside from Kiniksa Pharmaceuticals International, plc's ($KNSA) current $62.41 share price.
- Shares of KNSA traded near $59.2 on Monday, reflecting recent analyst activity.
- FMR LLC significantly increased its stake in KNSA, while Vanguard Portfolio Management LLC opened a new position.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 29, 2026, Wedbush analyst David Nierengarten reiterated his buy rating on KNSA, setting a price target of $72. This move comes as the stock traded around $59.2 on Monday.
Wedbush vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in KNSA
FMR LLC significantly increased its holdings in KNSA by 5,180,837 shares, bringing its total to 6,823,700 shares valued at approximately $328.6 million. Rubric Capital Management LP also added to its position, increasing by 421,347 shares to a total of 3,750,000 shares worth about $180.6 million. Meanwhile, Vanguard Portfolio Management LLC opened a new position with 1,766,268 shares valued at $85.0 million. In contrast, Acadian Asset Management LLC reduced its holdings by 376,730 shares, ending with 1,336,313 shares valued at $64.3 million.
Kiniksa Pharmaceuticals International, plc Stock Down 20.1%
Shares of KNSA traded near $59.2 on Monday. The company's recent analyst activities and institutional movements reflect an ongoing interest in its potential performance.
$KNSA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Kiniksa Pharmaceuticals International, plc
Several insider transactions were reported for KNSA. On June 1, 2026, Chairman and CEO Sanj Patel sold 900,000 shares. Richard Levy and Thomas Malley both made purchases of 2,799 and 12,158 shares, respectively, on May 29, 2026.
Analysts Set New Price Targets
On June 29, 2026, Wedbush maintained its buy rating with a $72 price target on KNSA. Canaccord Genuity and Citigroup also maintained buy ratings with targets of $64 and $60, respectively, on April 29, 2026. The consensus among analysts remains positive, with a buy recommendation and a mean target price reflecting optimism about the stock's future.
Bottom Line
Wedbush's reiteration of a buy rating and a $72 price target on KNSA underscores analyst confidence. Investors closely watch these ratings to gauge potential stock performance, though the 13F filings and insider activity provide a backward-looking view of institutional sentiment.
Get Kiniksa Pharmaceuticals International, plc alerts
New 13F filings, insider trades, and analyst moves on $KNSA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.